<DOC>
	<DOCNO>NCT02302404</DOCNO>
	<brief_summary>This study first administration GSK2982772 human . The study evaluate safety , tolerability , pharmacokinetics ( PK ) , exploratory pharmacodynamics ( PD ) single repeat oral dose 14 day GSK2982772 healthy male subject . This study plan include approximately 52 subject consist 2 part : Part A - single ascend dose , randomize , placebo control , 4 way crossover . In addition crossover treatment period , 8 subject cohort 2 participate additional treatment period receive GSK2982772 high-fat meal . Part B - repeat dose , randomize , placebo control , sequential-group . In cohort Part A ( Cohorts 1 2 ) , subject randomize equally ( 1:1:1:1 ) one 4 treatment sequence . Within period , allocation active placebo treatment 3:1 . In cohort Part B ( Cohorts 3 , 4 5 ) subject randomize GSK2982772 placebo 3:1 ratio . If require , subject additional cohort Part A ( Cohort 6 ) Part B ( Cohort 7 ) randomize GSK2982772 placebo 1:1:1:1 3:1 ratio , respectively . The study duration , include screen follow-up , expect exceed 105 day subject study .</brief_summary>
	<brief_title>A Safety Tolerability Study GSK2982772 , Single ( Both Fed Fasted States ) Repeat Oral Doses Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Male subject 18 65 year age inclusive , time signing informed consent . Healthy determine Investigator medically qualify designee base medical evaluation include medical history , physical examination , neurological examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator consultation Medical Monitor agree document find unlikely introduce additional risk factor interfere study procedure . Note : Screened subject laboratory value outside normal range may repeat inclusion study discretion Investigator . Body weight &gt; = 50 kilogram ( kg ) body mass index ( BMI ) within range 19 30 ( kilogram/squared meter ) kg/m^2 ( inclusive ) . Male subject female partner child bear potential must comply follow contraception requirement time first dose study medication least five halflives study medication last dose study medication followup visit , whichever longer . a. Abstinence , define sexual inactivity consistent preferred usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception ; b. Vasectomy documentation azoospermia ; c. Male condom plus partner use one contraceptive option : Contraceptive subdermal implant meet standard operation procedure ( SOP ) effectiveness criterion include &lt; 1 % rate failure per year , state product label ; Intrauterine device intrauterine system meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label ; Oral Contraceptive , either combined progestogen alone . Injectable progestogen ; Contraceptive vaginal ring ; Percutaneous contraceptive patch ; Occlusive cap ( female diaphragm cervical/vault cap ) vaginal spermicide ( foam , gel , cream suppository ) . These allow method contraception effective use consistently , correctly accordance product label . The Investigator responsible ensure subject understand properly use method contraception . Capable give sign informed consent , include compliance requirement restriction list consent form explain investigator . Alanine aminotransferase ( ALT ) bilirubin &gt; 1.5x Upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History active infection within 14 day receive study medication . Average QT duration correct heart rate Fridericia 's formula ( QTcF ) &gt; 450 millisecond ( msec ) three measure take least 5 minute apart semisupine position . History diagnosis obstructive sleep apnoea . History significant respiratory disorder . History current evidence febrile seizure , epilepsy , convulsion , significant head injury , significant neurologic condition . Unable refrain prescription nonprescription drug , include agent active central nervous system , vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication throughout study , unless opinion Investigator and/or GlaxoSmithKline Medical Monitor ( need ) medication interfere study procedure compromise subject safety . History regular alcohol consumption within 6 month study , define : For United Kingdom ( UK ) average weekly intake &gt; 21 unit male . One unit equivalent 8 gram ( g ) alcohol : halfpint ( approximately 240 millilitre [ mL ] ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . Current use history regular tobacco nicotinecontaining product use within 6 month screen . Subject must urinary cotinine level indicative nonsmoking status screen visit . Unwilling unable swallow multiple size 00 capsule part study participation History sensitivity study medication , component thereof history drug allergy , opinion Investigator and/or Medical Monitor ( appropriate ) , contraindicate participation . Subject receive vaccine ( either live attenuate nonlive ) within 30 day randomization OR plan receive live attenuate vaccine within 30 day + 5 halflives last dose study medication . Subjects impaired renal function define Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) Creatinine &gt; 1.6 milligram/decilitre ( mg/dL ) age appropriate glomerular filtration rate ( GFR ) &lt; =60 ( millilitre/minute [ mL/min ] /1.73 square meter [ m^2 ] ) estimate CKDEPI equation . A positive antinuclear antibody ( ANA ) elevate Creactive protein ( CRP ) outside normal reference range . Peripheral capillary oxygen saturation ( SpO2 ) &lt; 95 % room air . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . As potential magnitude immunosuppression compound unknown , subject presence hepatitis B core antibody ( HBcAb ) also exclude . A positive prestudy drug/alcohol screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . A positive tuberculosis test . Where participation study would result donation blood blood product excess 500 mL within 56day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Part B Specific Total cholesterol &gt; =300 mg/dL triglycerides &gt; =250 mg/dL . Subjects , Investigator/designee 's judgment , pose significant suicide risk . Evidence serious suicide risk may include history suicidal behavior and/or evidence suicidal ideation questionnaire ( e.g. , type 4 5 Columbia Suicide Severity Rating Scale [ CSSRS ] last 5 year ) . For Cohort 5 Only ( another Cohort Entero Test perform ) History gall bladder surgery gall bladder removal , history acute disease state ( e.g. , cholelithiasis ) within 14 day receive study medication .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>FTIH</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>GSK2982772</keyword>
	<keyword>safety</keyword>
	<keyword>Repeat dose</keyword>
	<keyword>tolerability</keyword>
</DOC>